ATE366939T1 - Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen - Google Patents

Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen

Info

Publication number
ATE366939T1
ATE366939T1 AT01945050T AT01945050T ATE366939T1 AT E366939 T1 ATE366939 T1 AT E366939T1 AT 01945050 T AT01945050 T AT 01945050T AT 01945050 T AT01945050 T AT 01945050T AT E366939 T1 ATE366939 T1 AT E366939T1
Authority
AT
Austria
Prior art keywords
liver fibrosis
diagnosis
serum marker
timp
mmp
Prior art date
Application number
AT01945050T
Other languages
English (en)
Inventor
Michael Voelker
Michael Becka
Werner Kroll
Andreas Knorr
Sylvia Unger
Mathias Gehrmann
Guido Hennig
Elmar-Reinhold Burchardt
Michael Arthur
Alastair Burt
Massimo Pinzani
Detlef Schuppan
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00109063A external-priority patent/EP1150123B1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE366939T1 publication Critical patent/ATE366939T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AT01945050T 2000-04-28 2001-04-26 Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen ATE366939T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109063A EP1150123B1 (de) 2000-04-28 2000-04-28 Diagnose von Leberfibrose mit Hilfe von Serummarkeralgorithmen
IT2001MI000813A ITMI20010813A1 (it) 2000-04-28 2001-04-13 Valutazione di fibrosi del fegato con algoritmi basati su marcatori del siero

Publications (1)

Publication Number Publication Date
ATE366939T1 true ATE366939T1 (de) 2007-08-15

Family

ID=29713312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945050T ATE366939T1 (de) 2000-04-28 2001-04-26 Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen

Country Status (7)

Country Link
US (1) US7141380B2 (de)
EP (1) EP1283989B1 (de)
AT (1) ATE366939T1 (de)
AU (1) AU6738001A (de)
DE (1) DE60129314T2 (de)
ES (1) ES2288962T3 (de)
WO (1) WO2001086304A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7668661B2 (en) * 2000-04-28 2010-02-23 Siemens Healthcare Diagnostics Inc. Liver disease-related methods and systems
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
US6986995B2 (en) 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US7517951B2 (en) 2002-12-24 2009-04-14 Nitto Boseki Co., Ltd. Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
CA2511482A1 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Method and system for disease detection using marker combinations
US7670764B2 (en) * 2003-10-24 2010-03-02 Prometheus Laboratories Inc. Methods of diagnosing tissue fibrosis
FR2870348B1 (fr) * 2004-05-14 2010-08-27 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet
ES2282780T3 (es) * 2004-08-12 2007-10-16 F. Hoffmann-La Roche Ag Metodo para el diagnostico de la fibrosis hepatica.
US7809170B2 (en) * 2006-08-10 2010-10-05 Louisiana Tech University Foundation, Inc. Method and apparatus for choosing and evaluating sample size for biometric training process
KR100999720B1 (ko) 2008-11-13 2010-12-08 아주대학교산학협력단 간 경변 진단을 위한 분석방법
WO2010065541A2 (en) 2008-12-02 2010-06-10 Tzu-Ling Tseng Biomarkers useful in liver fibrosis diagnosis
KR101018960B1 (ko) 2009-02-23 2011-03-02 아주대학교산학협력단 유의성있는 간섬유화 진단을 위한 분석 방법
WO2010097472A1 (en) 2009-02-26 2010-09-02 Universite D'angers Improved diagnosis of liver fibrosis or cirrhosis
EP2409154B1 (de) 2009-03-19 2017-08-02 Universite D'angers Nichtinvasives verfahren zur beurteilung des fortschreitens von leberfibrose
CN102020715B (zh) * 2010-10-22 2012-09-05 上海贝西生物科技有限公司 一种抗ⅲ型前胶原氨基末端肽单克隆抗体及其用途
EP2684513A1 (de) 2012-07-13 2014-01-15 Universite D'angers Verfahren zur Bereitstellung zuverlässiger, nichtinvasiver Diagnosetests
FR3023003B1 (fr) 2014-06-27 2016-07-15 Bio-Rad Innovations Combinaison synergique de biomarqueurs pour la detection et l'evaluation d'une fibrose hepatique
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
JP7007361B2 (ja) 2016-08-01 2022-01-24 センター ホスピタリア ユニバーシタイア ダンガース 複数標的線維症検査
PL425251A1 (pl) * 2018-04-17 2019-10-21 Uniwersytet Kazimierza Wielkiego Panel analityczny jako jeden z elementów wieloaspektowego procesu ustalającego stan zdrowia, dysfunkcji wątroby dla osób z zespołem zależności alkoholowej
CA3121162A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
US20250253047A1 (en) * 2022-04-20 2025-08-07 Siemens Healthcare Diagnostics Inc. Biomarkers for idiopathic pulmonary fibrosis and methods of producing and using same
ES2957479B2 (es) * 2022-06-07 2025-07-28 Baigene S L Metodo de obtencion de datos utiles para la prediccion del riesgo de un sujeto de sufrir fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060255A (en) * 1997-10-03 2000-05-09 Tosoh Corporation Type IV collagen high molecular form and production and diagnostic use thereof

Also Published As

Publication number Publication date
US20040053242A1 (en) 2004-03-18
WO2001086304A3 (en) 2002-04-04
US7141380B2 (en) 2006-11-28
DE60129314D1 (de) 2007-08-23
EP1283989A2 (de) 2003-02-19
DE60129314T2 (de) 2008-07-17
EP1283989B1 (de) 2007-07-11
WO2001086304A2 (en) 2001-11-15
ES2288962T3 (es) 2008-02-01
AU6738001A (en) 2001-11-20

Similar Documents

Publication Publication Date Title
DE60129314D1 (de) Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen
de Bock et al. Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer
DE602004022150D1 (de) Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
ATE331960T1 (de) Diagnose von myokardinfarkt und akutem koronarsyndrom durch kombination von markern
EP1116029A4 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE489633T1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
EP1492440A4 (de) Neues verfahren für die diagnose und prognose von malignen erkrankungen
DE60117592D1 (de) Diagnose von pre-eclampsia
ATE395812T1 (de) Methoden zur vorhersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
EP1130401A3 (de) Assays zur Bestimmung von Typ-II-Kollagenfragmenten in Harn
DE10082504D2 (de) Indikatorpeptid zur Diagnose und/oder Vorhersage von cardiovasculären und /oder endothelialen Erkrankungen, Antikörperzusammensetzung und immunoassay
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
EA200200435A1 (ru) Анализ лептина
ATE271225T1 (de) Verwendung von urintrypsininhibitor zur diagnose von aids
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
Siennicka et al. Tissue factor levels and the fibrinolytic system in thin and thick intraluminal thrombus and underlying walls of abdominal aortic aneurysms
CA2524708A1 (en) Use of protein cellular retinoic acid-binding protein ii (crabp ii) as marker for breast cancer
DE60225168D1 (de) Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür
DE602005010548D1 (de) Verbessertes verfahren zur diagnose des akuten koronarsyndroms
DE502006004619D1 (de) Verfahren zum Bestimmen der entzündungshemmenden Wirkung eines Peptids
ATE432364T1 (de) Sonden zum nachweis von tumorzellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties